Treatment with either pentamidine isethionate or trimethoprim-sulfamethoxazole significantly reduces the mortality of Pneumocystis carinii pneumonia. It is not known whether a combination might act in an additive, synergistic, or antagonistic manner. We studied the interaction of these two agents in the steroid-conditioned rat model of pneumocystosis. Of animals receiving pentamidine alone, 48% died and 45% had P. carinii cysts at autopsy. Trimethoprimsulfamethoxazole alone resulted in 21% mortality, and cysts were found in 28%. Both agents in full doses resulted in 45% deaths and cysts in 37%. Animals treated with half-dosages of pentamidine plus trimethroprim-sulfamethoxazole had mortality of 35%, and 21% had cysts. Trimethoprim alone, in two dosages, was ineffective in eradicating P. carinii cysts. The data suggest that combination therapy is no more effective than trimethoprim-sulfamethoxazole alone in the treatment of P. carinii pneumonia.
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Pneumocystis carinii is a protozoan which causes opportunistic pulmonary infection in immunosuppressed patients. Until the introduction of pentamidine isethionate (7) , mortality in immunocompromised hosts approached 100% (2, 12, 17) . Pentamidine isethionate therapy has reduced mortality to 30 to 50% (8, 14, 15, 17) . Because pentamidine is associated with a number of undesirable and toxic side effects, other therapeutic agents have been sought. Some success was noted using a combination of pyrimethamine and sulfadiazine (1, 9) , but the results were not always consistent (11, 13) . Experimental work by Hughes et al. (6) led to clinical trials of the fixed combination of trimethoprim-sulfamethoxazole in patients with P. carinii pneumonia (4, 10; W. T. Hughes, S. Feldman, and S. Chaudhary, Pediatr. Res. 10: 399A). These studies demonstrated survival rates equal to pentamidine and a lesser incidence of significant side effects.
The concomitant use of pentamidine isethionate and trimethoprim-sulfamethoxazole has not been studied. It is important to know whether such a combination has a therapeutic advantage without increased toxicity before it is administered to humans. The present study was (6) using similar experimental models of pneumocystis infection. The routes of administration are likewise considered standard in models of pneumocystis pneumonia in rats.
Pathology. The lungs were examined at the time of death; both impression smears and fixed sections were studied using toluidine blue 0. Typical cysts were required for the diagnosis of P. carinii infection. The severity of the infection was assessed by two independent observers who did not know the identity of the individual slides. A system of 0 to 4 was used wherein 0 = no P. carinii cysts seen; 1/2 = rare cysts; 1 = a few cysts in a few alveoli; 2 = a few cysts in many alveoli; 3 = half the alveoli filled with a moderate number of cysts; 4 = more than half the lung involved (1) 'Graded by number of cysts: 1, a few cysts in a few alveoli; 2, a few cysts in many alveoli; 3, half the alveoli filled with a moderate number of cysts; 4, more than half the lung involved. Animals treated with pentamidine isethionate alone (group 3) suffered a 48% mortality, and at autopsy P. carinii cysts were still present in 45%. The number of rats with P. carinii cysts following pentamidine therapy was significantly lower than in the positive control group (P = 0.02 by x2). The average disease scoring index was also decreased among survivors. The pentamidine injections were associated with skin necrosis, apparent abscess formation, and paralysis of the extremity nearest the injection site in all animals.
Trimethoprim-sulfamethoxazole therapy given alone (group 4) resulted in the lowest mortality, 21%, and autopsy evidence of P. carinii pneumonitis was found in 28%. There was a significant decrease in the number of animals with pneumocystis in this group compared with the positive control group (P < 0.001 by x2).
Among survivors, the average disease scoring index was much lower than that for either positive controls or pentamidine-treated animals, although not statistically significant.
Animals receiving trimethoprim-sulfamethoxazole plus pentamidine isethionate in full doses (group 5) had a mortality rate of 45% and P. carinii cysts on histological examination in 37%. When the half-dose of pentamidine isethionate was used in combination with trimethoprim-sulfamethoxazole (group 6), the mortality was 35% and P. carinii cysts were detected in 21%. Both combination therapy groups had significantly fewer rats with P. carinii cysts at autopsy compared with positive controls (P < 0.01 and P < 0.001, respectively, by x2). However, no significant differences were noted in comparing the combination groups with either agent alone. The average disease scoring index for each combination was lower than that of either drug alone.
Trimethoprim alone, administered at 10 mg (group 7) or 4 mg (group 8) daily, resulted in identical mortality rates (36%), and P. carinii cysts were demonstrated in 93% and 71%, respectively. The number of animals with pneumocystis was essentially the same as animals in the positive control group, and the average disease scoring index in survivors was the same or greater.
Healthy rats (non-steroid-conditioned) were used to detect adverse reactions to pentamidine. Daily injections of 4 mg of pentamidine isethionate (0.4% solution) uniformly resulted in bleeding, induration, and subsequent necrosis of skin. Several of the pentamidine group had transient paresis of the hind limb, which disappeared within 2 to 4 h. Of 10 rats receiving saline placebo, 8 did not develop signs of induration or necrosis. The remaining two rats inadvertently received a single injection of pentamidine; a small area of induration was detected over the injection site in these animals at the end of the experiment. During the study period, the treated animals averaged a smaller percent weight gain than the placebo group, but the difference was not statistically significant. DISCUSSION Six (21%) of the group 2 animals died during the experiment, a percentage considerably lower than that reported in the literature (5, 6, 16) . This discrepancy is best explained by differences in the periods of steroid conditioning. In the present study, the positive controls were sacrificed when the last therapeutic group had received a 2-week course of treatment (54 and 80 days of cortisone conditioning), whereas other investigators have continued cortisone until all animals died (median 78 [6] , 81 [16] , and 93 [5] days of steroids). Since 21 of 28 animals in group 2 had histological evidence of P. carinii pneumonitis at autopsy, it is expected that continued steroids would have resulted eventually in the death of the animals from extensive pneumocystosis. In contrast, none of the group 1 animals had demonstrable P. carinii cysts.
Mortality rates were highest in groups 3 (48%) and 5 (45%), animals treated with pentamidine at 4 mg/day alone or in combination with trimethoprim-sulfamethoxazole. However, survivors in group 5 had a much lower disease scoring index than rats in group 3. This difference may relate to the inherent toxicity of pentamidine isethionate. Skin necrosis, abscess formation, and paralysis of the injected limb seen in our experimental animals have been noted by others (1, 5, 16) . That pentamidine is the responsible agent was confirmed by the double blind study comparing pentamidine with a saline placebo in otherwise healthy animals. Even a single injection of pentamidine caused induration of the skin.
Animals treated with trimethoprim-sulfamethoxazole alone (group 4) had the lowest mortality, 21%, which was significantly lower than that for animals treated with pentamidine alone (P = 0.05 by x2). Statistically fewer animals in this group had P. carinii cysts demonstrated at autopsy compared with the untreated, cortisoneconditioned animals in group 2 (P < 0.001 by x2). The addition of pentamidine in half-dose to trimethoprim-sulfamethoxazole therapy (group 6) resulted in an increased mortality rate, although surviving animals did have a lower disease scoring index than those with either agent administered singly. Trimethoprim therapy VOL. 13, 1978 on August 27, 2017 by guest http://aac.asm.org/ 978 KLUGE, SPAULDING, AND SPAIN alone had little or no effect on mortality or in reducing the extent of pneumocystosis.
This study demonstrates that trimethoprimsulfamethoxazole alone is the most effective therapy for P. carinii pneumonitis in rats as judged by survival and number of animals with cysts at autopsy. Extrapolation of animal model data to the human equivalent of disease must always be done with extreme caution, and it should be emphasized that the present study results are truly applicable only to rats. However, it appears that these data provide preliminary answers to some of the editorial questions posed by Hughes (3): namely, a combination of trimethoprim-sulfamethoxazole with pentamidine isethionate is no more effective in the treatment of P. carinii pneumonitis than trimethoprim-sulfamethoxazole alone, and may be, in fact, harmful; trimethoprim by itself has no place in the treatment of pneumocystosis.
